Antares Pharma — Shareholder Meeting (May 2005)
51 slides from Antares Pharma's shareholder meeting presentation, May 3, 2005
Slide 1: Innovating Specialty Pharma
Innovating Specialty Pharma
Slide 2: Antares Pharma Annual Meeting, April 28, 2005
Antares Amex: Annual April ©2005 28, AIS Confidential Meeting Pharma, 2005 www.antarespharma.com Inc.
Slide 3: Safe Harbor
Safe Harbor This Litigation financial these unproven dependence reimbursement, with forward-looking ©2005presentation the forward-looking Confidential U.S. performance markets, Reform on Statement Securities third-party technological statements, may Act future of statements contain and Antares 1995.
Slide 4: Overview, Products, Platforms and Pipelines, Alliances, Financial Overview
Jack Stover: Products, Overview ©2005 Confidential Platforms and Pipelines Alliances and Partnerships Financial Overview Team Accomplishments and Goals Summary
Slide 5: Overview
©2005 Confidential Overview
Slide 6: Innovating Antares Pharma
“Innovating Antares ©2005 Confidential Pharma Pharma, Specialty Positioning Inc., is Pharma” a specialty pharmaceutical company focused on leveraging multiple drug delivery platforms to add value to existing drugs and to create new products for its customers
Slide 7: Specialty Pharma Market Performance
Overall Specialty 27.5% Total ?14% Source: ©2005 9.8%$207 Rx-a Confidential -a Performance Kline Market Pharma pharmaceutical a-billion Average and Market Company, annual companies growth presentation from $29 billion 2000-2003 at Drug Chemical & Associated Technologies, March 15, 2005
Slide 8: Business Drivers and Market Opportunity
Business Market Cost Lack Unique Consolidation Rise ©2005in of ofConfidential patent Drivers (NCE) business newness Modelexpirations of product opportunity big creates pharma development opportunity andcompanies cost controls Failure for and drug benefit rates blockbuster delivery (per generic phase
Slide 9: Antares Business Model and Technology Platforms
Antares Technology Gels Partner Platforms Solvay Specialty Continue Narrow Proof (Single Validation Commercial (Double Extraordinary ©2005Fast-Melt ofConfidential –Licensing digit Focus Pharma’s digit Concept HRT to Pharma support Development Expansion royalty) royalties) Returns gels Devices Genesi
Slide 10: Taking Control of Our Own Destiny
Taking We A Developing own ©2005 specialty are: products Confidential Control pharmaceutical a family Driving of Ourofto Own “lifestyle extraordinary company Destiny products” returns based upon our next generation drug delivery technologies Targeting large and growing markets and controlling develo
Slide 11: Merger History and Facilities
Merger History – 28 GMP 29 ©2005 Headquarters Pharma Devices employees patents approved Confidential of Development –Medi-Ject issued Minneapolis, –facility Exton with(MN) more in –PABasel, Switzerland MN and thanPermatec SW 100 applications for (SW) gels Prototype in 2001 pending Organized modeling
Slide 12: Products, Platforms and Pipelines
Products, ©2005 Confidential Platforms and Pipelines
Slide 13: Drug Delivery Technology Platforms
Technology Transdermal Fast-Melt Injection Advanced Local Systemic ATD™ Topical Easy Mini-Needle Vaccine ©2005 Tec™ Confidential Single Combination Delivery Intradermal Device Tablet Transdermal Oral Platforms Drug Disposable Gels Technology Dissolve Technologies Technology Delivery Injectors Gels D
Slide 14: Transdermal ATD Gels
Transdermal ATD™ Enabling developed, ©2005 elegance Confidential (Advanced technology marketed Drug Delivery Transdermal –and drug partnered residence Delivery) Creates timeGels flexibility sub-dermalinreservoir skin (formulation for systemic excipients) deliveryPatented over 24 hours formulation Ap
Slide 15: Competitive Advantage of Antares Gels
Competitive Antares Gels Accuracy Cosmetic smell Delivery Intellectual Applications Therapeutic Other development Alliances Green ©2005 Low More =Confidential Pharma Advantage Systemic, BioSante, Quality ofirritation, Property than Levels Dose Positioning OAB, Proprietary ATD™ one Gel Unit-dose Topi
Slide 16: Gel Portfolio
Gel Portfolio AP-1034 AP-1081 Estradiol Testosterone E2/NETA NSAID ibuprofen ©2005 Confidential Gel Gel OAB Contraceptive marketed HT Pain Gel Hot Phase Phase FSD Preclinical flashes IIIIPhase Preclinical Complete /II Phase III
Slide 17: AP-1034 Oxybutynin Gel for Overactive Bladder
IND Antares U.S. patent – Expect ©2005 505(b)(2) Single Filed (19m) field Confidential toPharma’s study be for and Positive pathway inAP-1034 Phase Phase Europe lead FDA verified III III gel with Gel confirmed around pre-IND product; for higher Treatment year meeting currently percentages end Compet
Slide 18: AP-1034 Marketplace Analysis
AP-1034 Products – Antares ©2005 Vesicare Detrol/Detrol Ditropan Oxytrol Enablex Sanctura Confidential oxybutynin in Gel Patch (Novartis) (Yamanouchi) (Indevus) XL Marketplace Pipeline – (J&J) Competitive LA (Watson) (Pfizer) gel Dry 29% 20 7.5mg targets mg Market Mouth 5mg 2% $400m 69% 20% 20%/15mg
Slide 19: AP-1081 Contraceptive Gel
AP-1081 New Based issues ©2005delivery of on Confidential patches Contraceptive ORTHOroutes Second EVRA® andATD™ convenience consecutive actives GelsLarge gel are product differentiators market for opportunity Antares Apriloutside over 2005$2 – of Announced billion HT market in U.S. successful Minim
Slide 20: Estradiol Gel Phase III Results
Estradiol “Well Treat controlled) filings ©2005 moderate positioned by Confidential ATD™ Antares completed toto Gel severe Pharma compete (?) with Phase hot expected 483 in flashes III $2.5 patients Results early billion and Study vaginal 2006 Announced U.S. included hormone atrophythree Gels therap
Slide 21: Testosterone Gel for Female Sexual Dysfunction
Testosterone Female “…transdermal Currently Recent Will European Positive ©2005receive Confidential estimate Sexual Phase market no milestones ATD™ RxII Dysfunction gel of product results believed U.S.market technologies Geland in available (?)to U.S. Therapy royalties bepotential in as …are 46 larg
Slide 22: FDA Panel Review of Intrinsa
FDA Panel expressed – may ©2005 First Second be Review voted study Confidential beneficial study support 14 (in Perspective to (3-year nonhysterectomized 3for ifthat able LibiGel™(Rich safety) Intrinsa™ to onshow Intrinsa™ nearpositive provides completion women) Watson, results “ahas analyst clinica
Slide 23: E2/NETA Partnered with Solvay
E2/NETA Partnered big ©2005 thing” Confidential with Combination in drug Solvay delivery Pharmaceuticals GelPhase for HT I trials(who complete grewClinical Androgel® protocol to over for$500m) Phase III Leverages expectedAntares to be confirmed Pharma’swith unique FDAability shortly to deliver two A
Slide 24: NSAID Ibuprofen Gel
NSAID Ibuprofen Treatment large multiple ©2005 market Confidential ATD™ actives /ofOther opportunity mild Gels inCompounds to same moderate gel withEvaluating Cox2 inflammatory inhibitor data toand post-market present localized to FDA clinical painand symptoms results Canadian (Vioxx®, Ibuprofen aut
Slide 25: Transdermal Delivery Market
Transdermal US$ 35 2005 Source: ©2005 30(Billions) 2015 25Confidential Jain 20 15 PharmaBiotech Delivery 10 5 0 $12.7 Market$31.5 – April 2005
Slide 26: Gel Pipeline
Gel = Formulation Estradiol ATD™ AP-1034 DC1 Licensed (pain, NSAID NA ©2005 Pipeline North inflammation) Confidential Gel ATD™ ATD™ in (oxybutynin for 11 America Preclinical Ibuprofen NA—BioSante Gel Gel(pain, Canada NA—BioSante EU ) ATD™ Clinical = gel inflammation) Europe countries orWomen gel Jap
Slide 27: Easy Tec Fast-Melt ODT
Easy cost Growing Rapidly growing markets Low ©2005Tec™ Confidential Fast-Melt dissolves atmarket to20% –achieve Fast-Melt per in ODT year commercialization mouth ODT Tablets Formulating / patient Technology friendly ANDACNS, strategy pain, forallergy, approvalobesity Internal Conventional pipeline
Slide 28: First Easy Tec Product Development
Firstnot Developed Use ANDA Pre-IND/IND ©2005 Easy Confidential pathway associated Tec™ NSAID documentation confirmed ODT with in field Product an increase of Bioequivalence underway arthritic in more pain determined serious side effects of coxib use Large and growing product opportunity without cur
Slide 29: Competitive Oral Disintegrating Technologies
Competitive Oral Antares GRAS Disintegration Drug Strength/Stability high Manufacturing Process Packaging Taste Other ingredients Green ©2005Disintegrating temp/humidity Loading Masking Compatible =Yes Confidential equipment Pharma Advantage Blister Yes First Position 2time Customized Direct Yes –Ea
Slide 30: Vibex Mini-Needle Injection Devices
Vibex™ Proprietary Large – Hidden Medi-Jector ©2005 Quick Lessmarket pain Confidential needle, injection Injection and than Vibex™ opportunities shield cost other avoids Devices effective (AJ1) locks needle-based incomplete Disposable –after New Under use biotech devices injection development for Mi
Slide 31: Competitive Vibex Position
Competitive Vibex™ Antares Safety “Never Pre-Filled Intellectual Ease Intended Speed Dose Green ©2005 of Fixed = of Mechanism Confidential see Use Pharma Advantage vs. Delivery Injection Yes the Property Up Disposable 2Position steps –needle” toAJ3/AJ4 Hypak 1.0 (mini-needle (fast /3Retraction Paten
Slide 32: Valeo Needle-Free Injection Devices
Valeo™ High-pressure Currently – Next ©2005 Wal-Mart Ferring Newgeneration U.S. Confidential / (Europe); Vision® marketed approved markets stream licensed Injection JCR inas of hGH vendor fluid (Japan); to Lilly field Devices penetrates (2004 by diabetes SciGen partners Reusable skin (Asia) / obesit
Slide 33: Valeo Re-launch Marketing Plan
Valeo™ Re-launch Most Developing Adding Price Completed – Strengthen Revise Support ©2005 Product Place Price Promotion sensitivity advanced patient Confidential new MD / Vision® in message Medical distribution vendor evaluation 2Qwebsite needle-free confirmed 2005 Marketing reimbursement sites to c
Slide 34: Valeo Competitive Position
Valeo™ Antares Minimum/Maximum Maintenance Power Size/Weight Warranty Syringe Sharps Injection Application Price Green ©2005 Approx =Source Disposal Confidential Pharma Use Advantage /Depth Two Vision® Insulin 6One Required $300 Spring in Years Subcutaneous VISION® Issues /week 4.6 Competitive $250
Slide 35: Valeo Global Market Opportunities
Valeo™ Global Publications Market Worldwide U.S. Lilly’s ©2005diabetic insulin-using U.S. insulin Confidential growth Needle-Free diabetic insulin-using market suggest population competing opportunities: diabetics for population 4/5 Injection insulin –prefer diabetics market 17– million early 4–Devi
Slide 36: Estimated Insulin Needle-Free Injection Sales
Estimated (in 450 Insulin Source: 2007 2002 Needle-free ©2005 Millions) 400Confidential 54% Greystone 350 Needle-Free Injection, 300 250 Associates, 200 June Injection 150 2003100 Sales 50 0 $425 $195 $230 $10.3 all other 46%
Slide 37: Device Pipeline
Device Concept Vision® Antares (needle-free SciGen Valeo™ Lilly needle-free Vibex™ mini-needle AJ3 AJ4 AJID Proprietary ©2005 products (short (long (next (vaccines) Confidential Pipeline –for Prototype Platforms for Asia prefill) prefill) generation AJ injector) Insulin injectors) Insulin hGH inject
Slide 38: Alliances and Partnerships
Alliances ©2005 Confidential and Partnerships
Slide 39: Corporate Partners
Corporate ©2005 Confidential Partners
Slide 40: Financial Overview
Financial ©2005 Confidential Overview
Slide 41: Financial Summary
Antares AMEX Average 52-week Market Shares Fully Approx. 2004 Cash Debt * ©2005 as ofNone Revenue &diluted outstanding 03/21/2005 Confidential Cap* Symbol cash Pharma diluted daily range* equivalents shares $50 volume $2.7 AIS shares $0.60 –mFinancial 40 m outstanding (30 m -“in $1.84 atday)* the 12
Slide 42: Key Financial Items
Financial Key (Millions) Total Margin Operating Other Net Average ©2005 Loss Statement Revenue Margin Income Confidential monthly (8.3) per Summary Expense Loss 2004 %Common 1.4 (Expense) (32.8) 50% $2.7 of (8.4) 2005 1.8 cash Operations 9.7 $3.8 47% (8.6) burn Share 10.4 0.026 $0.638 ($0.23) Items
Slide 43: Key Balance Sheet Items
Financial (Millions) Cash Accounts Current Total Deferred Shareholder All ©2005 Liabilities Assets $9.6 Confidential Assets Revenue Summary Receivable $1.9 2004 Equity $13.2 &10.1 2005 Equity $3.9 $5.9 8.2 Key 2.7 0.30.3 $4.4 $13.2 Balance 0.5 $5.9 Sheet Items
Slide 44: Team
ntares af tares pt a oo = > Team Bie 7 Tareas
Slide 45: Management
JackDario Management Dr. American Lawrence Mike ©2005E. Kasprick Confidential Stover Carrara M. Biosystems, Christian ––business management – strong and – extensive development, technical Molecular and financial financial background Genetics marketing experience experience James inand formulations H
Slide 46: Board of Directors
Board Dr. and Pharmaceuticals Thomas ©2005 Jacques Company of Confidential J.Directors Garrity Gonella Dr.Dr. Rajesh – AdvancePCS; –Paul founder C. K. Shrotriya Wotton of Antares Eli – –President Lilly Chairman,CEO Pharma; and Company and founder CEOand of Jack ofPresident Topigen JGE.Consulting; St
Slide 47: Accomplishments and Goals
Accomplishments ©2005 Confidential and Goals
Slide 48: Recent Accomplishments
Recent Commercially Completed – Added ©2005 Testosterone Estradiol E2/NETA seasoned Accomplishments Confidential gel formulation (Phase focused gel (Phase executive, (Phase II) III business ofcomplete) IIAP-1081 James complete) model Hattersley transdermal Gainedaslisting Vice contraceptive Presiden
Slide 49: Target Goals for 2005
2005 Complete Target for ©2005 Vision® Goals quality, Confidential pivotal Manage complementary Phase net I/II burnforrate product oxybutynin to reasonable or technology gel; Phase rate New III planning major business Preparedevelopment to file ANDAdeals for first validating Easy Tec™ business produ
Slide 50: Antares Summary
Antares “Innovating Positioned Established Internal gel ©2005 Experienced Confidential pipeline Summary inglobal Specialty a novel and ofpartners products dynamic and Pharma” growing - being Lily, management Solvay, “lifestyle developed BioSante, team products” in specialty and Ferring Board sector
Slide 51: Thank You
Thank You Specialty Pharma Innovating